Ken Griffin Jasper Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.42 - $0.93 $12,474 - $27,621
-29,700 Reduced 43.11%
39,200 $30,000
Q3 2023

Nov 14, 2023
BUY
$0.68 - $1.54 $33,592 - $76,076
49,400 Added 253.33%
68,900 $48,000
Q2 2023

Aug 14, 2023
BUY
$1.19 - $1.79 $15,470 - $23,270
13,000 Added 200.0%
19,500 $26,000
Q1 2023

May 15, 2023
BUY
$1.48 - $2.74 $9,620 - $17,810
6,500 New
6,500 $11,000

Others Institutions Holding JSPR

# of Institutions
1
Shares Held
5.63M
Call Options Held
0
Put Options Held
0
View Full List

About Jasper Therapeutics, Inc.

JSPR Quotes by TradingView
  • Ticker JSPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,073,300
  • Market Cap $807M
  • Description
  • Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a techniqu...
More about JSPR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email